Thomas Chen
Tracked across 1 events · 7 articles · First seen Aug 26, 2026 · Last active Aug 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Neonci Technologies reported positive topline results from its NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint with 48.9% six-month progression-free…
Impact: Director Thomas Chen's share purchases also indicate insider confidence in NeOnc's prospects.
Aug 26, 2026 · 7 articles
40
Thomas Chen purchased shares Neonci TechnologiesNeOnc NEO100 Phase 2a Results
ERGEN INTELLIGENCE
Track Thomas Chen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard